RxDoctor Payments Data

David Taylor, MD

Psychiatry · Goshen, INNPI 1184623027

Payments from drug & device makers

$563in general payments, 2019–2025

Across 17 payments — averaging $33.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$155
  • Teva Pharmaceuticals USA, Inc.$139
  • Otsuka America Pharmaceutical, Inc.$85
  • Vanda Pharmaceuticals Inc.$50
  • Alkermes, Inc.$38
  • Axsome Therapeutics, Inc.$30
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$45280%
  • Education$11120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$563 in reported general payments places this provider in the 55th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$15,889
Medicare patients
57
Services billed
195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil22$48,902
Invega SustennaPaliperidone Palmitate21$37,410
EmsamSelegiline12$23,329
CaplytaLumateperone Tosylate12$20,240
Aripiprazole67$6,147
Bupropion XlBupropion Hcl98$5,781
Tranylcypromine Sulfate16$4,682
Alprazolam ErAlprazolam44$1,720
Desvenlafaxine Succinate ErDesvenlafaxine Succinate45$1,504
Clozapine31$1,441
Selegiline Hcl25$1,406
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$1,379
Quetiapine Fumarate138$1,363
Mirtazapine95$1,308
Lamotrigine90$1,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada$38$48,90222 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$155$20,24012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 514 psychiatry providers in Indiana.

Other psychiatry in Goshen

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →